Study: New antibody blocks dengue virus

While Sanofi has been working long and hard on a promising late-stage dengue vaccine, investigators in the field believe that there are some real limitations to its effectiveness. Now a team led by Duke-NUS Graduate Medical School Singapore has discovered an antibody which they say has demonstrated a powerful effect against the dengue virus, pointing to a possible new therapy that can fight it.

MD Anderson team explores a combination approach against cancer metastasis

Researchers at The University of Texas MD Anderson Cancer Center say they've devised a new strategy for attacking breast cancer tumors before they metastasize.

UC San Diego group zeroes in on breaking a link between obesity and diabetes

Investigators at the University of California-San Diego say they've identified a crucial link between obesity and diabetes, and now they're zeroing in on a new drug that can break it.

Alzheimer's study finds a molecule that might stymie critical stage of the disease

Scientists at some of the most prestigious research institutions in the U.K. and Sweden say they've found a molecule that could disarm the toxic clusters of amyloid beta that are believed to trigger Alzheimer's, offering a new approach to treating the disease.

Langer team offers up a hydrogel drug delivery vehicle at MIT

Researchers in the lab of MIT's Robert Langer have created a hydrogel that's designed to be much better than current technologies in getting drugs into patients and straight to where they are targeted.

CRISPR project points to a new approach on Duchenne muscular dystrophy

Investigators at Duke have turned to a new gene-editing tool to come up with a new approach to Duchenne muscular dystrophy that theoretically could apply to a majority of the boys afflicted with the fatal rare disease.

Stem cell work points to new approach on fighting obesity

Investigators at Queen Mary University of London say that by regulating the length of primary cilia on stem cells they could prevent them from turning into fat cells--a possible new direction in obesity research.

Investigators advance a new therapy to use against pneumonia, influenza

Scientists say they've completed a successful mouse study of a new antibody designed to spur the recovery of patients suffering from pneumonia and influenza. And they're now preparing for human studies.

Science team spotlights a potentially game-changing approach for ovarian cancer

Researchers at the Wistar Institute say that they have zeroed in on a potential new therapeutic target for a subset of the most aggressive cases of ovarian cancer. And they're heralding the discovery as a big step toward the first effective therapy for the lethal disease.

Singapore research team develops new strategy on inflammation cancer targeting

A research team at the National University of Singapore has published a paper on a novel strategy to prevent progression of inflammation-associated cancers.

Alzheimer's group spawns three new R&D centers to advance promising therapies

Alzheimer's Research UK is setting up a trio of discovery units in the Golden Triangle with plans to recruit dozens of investigators to advance new work on therapeutics for the memory-robbing disease.

Scientists pursue new compounds that can tackle inflammatory diseases

Investigators have known for some time that fasting, intense exercise or a low-carb diet can spur production of a compound called BHB, or β-hydroxybutyrate. Now investigators say they have nailed down proof that BHB can directly inhibit the inflammatory protein NLRP3, which could have an impact in treating a range of diseases linked to inflammation, like diabetes, Alzheimer's, atherosclerosis and autoinflammatory conditions.

Peptide could play a role in preventing binge eating, obesity

Shifting focus from the hypothalamus to the amygdala, investigators at Boston University say that an injection of a peptide and hormone reduced appetite in an experimental model, pointing to a new approach to treating obesity and binge eating.

Psychedelic drug shows promise as a new treatment for allergic asthma

Over the last few years, testing psychedelic drugs against depression and other diseases of the brain has once again grown fashionable in some drug research groups. But now a team from Louisiana State University says that they have preclinical evidence to suggest that one of those drugs in the neurosciences spotlight--(R)-DOI (2,5-dimethoxy-4-iodoamphetamine)--could work against allergic asthma.

Neuroscience project tries to put the immune system to work against Alzheimer's

Neurogeneticists at the University of Southern California say that they were able to use immune cells to clear away amyloid beta, the toxic protein that may be the cause of Alzheimer's.

UC Davis team finds a prime drug candidate for neuropathic pain

Neuropathic pain has been linked closely to microglia, immune cells in the spinal cord which are known to release cytokines and other chemicals including nitrous oxide in the wake of peripheral nerve damage. A team of UC Davis researchers says that inhibiting nitrous oxide at the time that nerve damage is done could prevent neuropathic pain from occurring later. And they've found a compound that they say is very effective at doing just that.

Cancer researcher says animal study supports new approach to lung cancer

Oncology investigator Xiaoyang Qi says that he's wrapped another animal study that demonstrates the potential of a combination of cellular components into a treatment that's able to vanquish cancer cells.

Antibody developed by NTU-led team in Singapore tracks flu recovery

SINGAPORE--Nanyang Technological University (NTU) researchers in Singapore working with colleagues at other local institutions have developed an antibody with the potential to help patients suffering from pneumonia and influenza to recover faster, NTU said in a news release.

Dartmouth team tags HER4 as a key culprit for HER2 drug resistance

Cancer drug researchers have developed some major new drugs for treating HER2-positive breast cancer, but patients still develop resistance to them. Now a team at Dartmouth says it has identified a key pathway for resistance that points to a new class of third-line therapies.

Cleveland Clinic team posts a big target for CKD drug developers

Scientists at the Cleveland Clinic say that they have nailed down solid evidence that the gut metabolite trimethylamine N-oxide is directly responsible for chronic kidney disease. And aside from trying to develop a new dietary program, they're offering it up as a target for drug developers interested in pursuing the pathways involved in the disease.